Abstract
ABSTRACTDosing patterns with second-generation antipsychotic medications (SGAs) are dynamic, with some SGAs surpassing current recommendations while others are declining in dose since their initial regulatory guidelines. Pertinent recent studies and available pharmacoepidemiologic reports, information, and expert consenses are reviewed herein to illuminate current thinking on the topic of dosing with SGAs. There is a need for fixed-dose studies of each SGA. Additionally, dosing should be a primary consideration when designing and subsequently interpreting comparative studies between SGAs.
Publisher
Cambridge University Press (CUP)
Subject
Psychiatry and Mental health,Neurology (clinical)
Reference64 articles.
1. Broad effectiveness trial with aripiprazole;Riera;Schizophr Res.,2004
2. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia
3. Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic Schizophrenia
4. Ziprasidone vs risperidone in schizophrenia: 52-wcek randomized, double-blind comparison;Addington;Schizophr Res.,2004
5. High-dose ziprasidone is associated with marginal additional Qtc increase;Micelli;Schizophr Res.,2004
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献